This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SABCS 2020
Presentations

Tucatinib | Breast Cancer | Abstract 117
Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status

Tucatinib | Breast Cancer | Poster PD13-04
Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with active brain metastases

Tucatinib | Research | Abstract 1290
Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer

Tucatinib | Breast Cancer | Abstract 109
HER2CLIMB-02 TIP: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

Ladiratuzumab vedotin | Breast Cancer | Abstract 410
SGNLVA-001 TIP: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

HEOR | Breast Cancer | Abstract 130
Real world treatment patterns and healthcare resource utilization among HER2+ metastatic breast cancer patients with and without brain metastases: a retrospective cohort study
Videos
Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status
Tucatinib | Breast Cancer | Abstract 117
Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with active brain metastases
Tucatinib | Breast Cancer | Poster PD13-04